Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Glioblastoma 7Colorectal Neoplasms 6Gliosarcoma 5Neoplasm Metastasis 4Colonic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Rectal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solitary Fibrous Tumor, Pleural 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Mesothelioma, Malignant 2Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

Fulvestrant 5Anastrozole 4Letrozole 3Docetaxel 2Dasatinib 2vandetanib 1sonidegib 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1irinotecan sucrosofate 1exemestane 1cediranib 1XMT-1522 1Vorinostat 1Tablets 1Ritonavir 1Population Groups 1Paclitaxel 1Moxifloxacin 1Itraconazole 1Histone Deacetylase Inhibitors 1Gemcitabine 1FCN-437c 1Everolimus 1Electroporation 1Cryosurgery 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Breast Cancer × cediranib × Clear all
NCT00454805 2016-08-03

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

AstraZeneca

Phase 2 Completed
75 enrolled 11 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡